Recent Updates
Recently added Catalysts
WVE

Wave Life Sciences Initiates Two Phase 1b/2a Clinical Trials: PRECISION-HD1 and PRECISION-HD2 in Patients with Huntington’s Disease

Monday, July 24, 2017 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Wave Life Sciences Initiates Two Phase 1b/2a Clinical Trials: PRECISION-HD1 and PRECISION-HD2 in Patients with Huntington’s Disease

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+13%
120-day peak, hindsight
Typical move
33.2%
average across 9 past catalysts
Cash runway
~27 mo
Minimal dilution risk
Lead asset
WVE-N531
Phase 2 · Duchenne Muscular Dystrophy

Full Press Release Details

Wave Life Sciences Initiates Two Phase 1b/2a Clinical Trials: PRECISION-HD1 and PRECISION-HD2 in Patients with Huntington’s Disease.
ShareAdd on Google
Tags: WVE Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Jul 24, 2017

Biotech snapshot

Cash runway
$491M liquidity · $18M/mo burn
~27 mo
Minimal dilution risk
Lead asset
WVE-N531Phase 2
Duchenne Muscular Dystrophy →

Catalyst track record

+13%
best trade around WVE's most recent catalyst

Peak hindsight return over a 120-day window, across 9 tracked FDA/PDUFA catalysts for WVE.

See every catalyst's timing & PoA →